Treatment
Share your love
Q&A: Anat Loewenstein recaps the 2025 EURETINA meeting | Ophthalmology Times
Photo of Anat Loewenstein at EURETINA 2025 The 25th EURETINA conference was a landmark event, attracting 11,000 participants from around the world. Anat Loewenstein, MD, the 2025 The president of EURETINA, highlighted the meeting’s comprehensive scientific program, featuring sessions on…
Justis P. Ehlers, MD, on the HELIOS trial for NPDR | Ophthalmology Times
Note: Captions are generated with the assistance of AI. Justis Ehlers, MD, spoke with Ophthalmology Times to share key findings from his recent presentation at the 2025 Retina Society meeting, which was held in Chicago, Illinois. Ehlers shared data from…
Q&A: Camiel Boon presents the must-knows signs of central serous chorioretinopathy | Ophthalmology Times
Photo of Camiel Boon at the 2025 EURETINA meeting in Paris, France In this interview, Professor Camiel Boon from Amsterdam UMC and Leiden University Medical Center discussed central serous chorioretinopathy (CSC). He explored the disease’s pathophysiology, highlighting choroidal hyperpermeability and…
Optos and Toku to incorporate BioAge AI into existing retinal imaging devices | Ophthalmology Times
(Image credit: AdobeStock/hakule) Optos and Toku have reached an agreement to make Toku’s BioAge available to users of Optos Daytona, Monaco, MonacoPro, and California devices in the United States. The companies state that by incorporating the AI solution, BioAge, eye…
Q&A: Robyn Guymer highlights risk factors of intermediate AMD | Ophthalmology Times
Photo of Robyn Guymer at EURETINA 2025 in Paris, France Professor Robyn Guymer from the University of Melbourne discussed intermediate age-related macular degeneration (AMD) at the 2025 EURETINA meeting. She explored risk factors for disease progression, focusing on optical coherence…
iVeena secures $2 million NEI SBIR grant to advance pediatric myopia therapy | Ophthalmology Times
iVeena Delivery Systems has been awarded a $2 million phase 2 Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH). The funding will help to advance development of novel topical eye…
Christine Kay, MD, on the 152-week results of the RESTORE study for retinitis pigmentosa | Ophthalmology Times
Christine Kay, MD, a vitreoretinal surgeon and IRD specialist from Gainesville, Florida, presented the results of the RESTORE trial for MCO-010 optogenetic therapy for retinitis pigmentosa. The trial was a 152-week analysis of a novel gene therapy targeting bipolar cells.…
Part 6: What if? Curing any eye disease with the snap of your finger | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts in the field, in a perfect world, if they had the ability to cure one eye disease or condition in the snap of their finger, what they would choose…
Horus Pharma selected as additional commercialization partner for aflibercept biosimilar in Europe | Ophthalmology Times
(Image credit: AdobeStock) Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of Formycon’s Eylea1 biosimilar FYB203 (aflibercept), issued an additional semi-exclusive license agreement with Horus Pharma for the commercialization of FYB203/Baiama 2 in selected European countries.1…
Q&A: Stela Vujosevic shares why the staging system for diabetic eye conditions should be updated | Ophthalmology Times
Photo of Stela Vujosevic at the 2025 EURETINA meeting in Paris, France Stela Vujosevic, Md, PhD, FEBO, presented the need for a new staging system for diabetic retinopathy and diabetic macular edema at the 2025 EURETINA meeting in Paris, France.…